The 5 constituents in the munKNEE Psychedelic Drug Stocks Index went down 1.6% the second week of December, on average, and are now down 11.5% YTD, on average.Below is how they performed this week, in descending order.
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- is focused on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Read: atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- is researching and developing therapies and products with the world’s largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
Summary
The munKNEE Psychedelic Drug Stocks Index was down 1.6% this week and is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, was up 3.8% but remains down 28.8% YTD.More By This Author:Canadian Cannabis LP Stocks Index Down 5% This Week – Here’s Why
These 6 AI-Capable PC Stocks Should Rise Considerably In 2024/25
Get Invested Now: AI-Enabled PCs Are Coming In 2024
